Moleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting [Yahoo! Finance]
Moleculin Biotech, Inc. (MBRX)
Last moleculin biotech, inc. earnings: 8/16 05:35 pm
Check Earnings Report
US:NASDAQ Investor Relations:
moleculin.com/investors
Company Research
Source: Yahoo! Finance
announced that an abstract highlighting data on its lead drug candidate, annamycin, has been accepted for poster presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting , taking place May 29 – June 2, 2026, in Chicago, Illinois. The abstract, titled “Cardiac safety of L-annamycin at high cumulative anthracycline exposure: Pooled analysis,” will be presented in a poster session focused on Symptom Science and Palliative Care. Presentation Details: Session Type: Poster Session - Symptom Science and Palliative Care Presentation Date and Time: May 30, 2026, 1:30 PM – 4:30 PM CDT Location: Poster Board #8 The abstract presents a pooled analysis evaluating the cardiac safety profile of annamycin in patients with high cumulative exposure to anthracyclines, an important consideration given the known risk of cardiotoxicity associated with this class of chemotherapeutic agents. “We are pleased to have this abstract accepted for presentation at ASCO, one
Show less
Read more
Impact Snapshot
Event Time:
MBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MBRX alerts
High impacting Moleculin Biotech, Inc. news events
Weekly update
A roundup of the hottest topics
MBRX
News
- Moleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual MeetingGlobeNewswire
- Moleculin Releases Next CEO Corner Segment Highlighting Annamycin’s Non-Cardiotoxic ProfileGlobeNewswire
- Moleculin Biotech files to sell 6.37M shares of common stock for holders [Seeking Alpha]Seeking Alpha
- Moleculin Biotech (MBRX) had its "buy" rating reaffirmed by HC Wainwright. They now have a $22.00 price target on the stock.MarketBeat
- Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout [Yahoo! Finance]Yahoo! Finance
MBRX
Analyst Actions
- 3/24/26 - HC Wainwright
MBRX
Sec Filings
- 4/15/26 - Form 8-K
- 4/15/26 - Form EFFECT
- 4/14/26 - Form 10-K/A
- MBRX's page on the SEC website